TOT BIOPHARM International Co. Ltd.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: HK0000545266
HKD
4.20
2.27 (117.62%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Golden Throat Holdings Group Co., Ltd.
Dawnrays Pharmaceutical Holdings Ltd.
Shanghai Henlius Biotech, Inc.
TOT BIOPHARM International Co. Ltd.
Hua Medicine Ltd.
Immunotech Biopharm Ltd.
Transcenta Holding Ltd.
Abbisko Cayman Ltd.
Zhaoke Ophthalmology Ltd.
CStone Pharmaceuticals Co. Ltd.
China Regenerative Medicine International Ltd.

Why is TOT BIOPHARM International Co. Ltd. ?

1
Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 0.78%
  • Poor long term growth as Operating profit has grown by an annual rate 18.76% of over the last 5 years
  • High Debt Company with a Debt to Equity ratio (avg) at times
2
With ROE of 0.95%, it has a Expensive valuation with a 2.12 Price to Book Value
  • Over the past year, while the stock has generated a return of 133.33%, its profits have risen by 279.5% ; the PEG ratio of the company is 0.8
stock-recommendationReal-Time Research Report

Verdict Report

How much should you sell?

  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is TOT BIOPHARM International Co. Ltd. for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
TOT BIOPHARM International Co. Ltd.
-100.0%
0.95
94.17%
Hang Seng Hong Kong
18.06%
0.71
25.51%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
133.77%
EBIT Growth (5y)
18.76%
EBIT to Interest (avg)
-59.45
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0.53
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0.45%
ROE (avg)
0.78%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
224
Industry P/E
Price to Book Value
2.12
EV to EBIT
-493.33
EV to EBITDA
22.62
EV to Capital Employed
2.10
EV to Sales
1.49
PEG Ratio
0.80
Dividend Yield
NA
ROCE (Latest)
-0.43%
ROE (Latest)
0.95%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bearish
Bearish
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

0What is working for the Company
Icon
NO KEY POSITIVE TRIGGERS
-7What is not working for the Company
INTEREST(HY)

At HKD 6.84 MM has Grown at 62.6%

RAW MATERIAL COST(Y)

Grown by 5.46% (YoY

PRE-TAX PROFIT(Q)

Fallen at -85.55%

NET PROFIT(Q)

Fallen at -85.55%

Here's what is working for TOT BIOPHARM International Co. Ltd.

Depreciation
Highest at HKD 41.89 MM
in the last five periods
MOJO Watch
The expenditure on assets done by the company may have gone into operation

Depreciation (HKD MM)

Depreciation
At HKD 41.89 MM has Grown at 12.1%
period on period (QoQ)
MOJO Watch
The expenditure on assets done by the company has gone into productive use which should positively reflect in the future sales

Depreciation (HKD MM)

Here's what is not working for TOT BIOPHARM International Co. Ltd.

Interest
At HKD 6.84 MM has Grown at 62.6%
over previous Semi-Annual period
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (HKD MM)

Pre-Tax Profit
Fallen at -85.55%
Year on Year (YoY)
MOJO Watch
Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (HKD MM)

Net Profit
Fallen at -85.55%
Year on Year (YoY)
MOJO Watch
Near term Net Profit trend is negative

Net Profit (HKD MM)

Raw Material Cost
Grown by 5.46% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales